Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 436-010-0 | CAS number: 422278-61-3 PRIMID V40-32
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: Assessment report of toxicokinetic behaviour
- Adequacy of study:
- other information
- Conclusions:
- Absorption rates were determined to be 100% for all routes of exposure, assuming a worst case scenario.
No bioaccumulation of the substance in the body is expected. - Executive summary:
The toxicokinetic behavior after exposureto the substanceN,N-bis(2-hydroxypropyl-)benzamide(PRIMID V 40-32) is assessed in this report.
No relevant testing has been done by now to generate analytical toxicokinetic data forN,N-bis(2-hydroxypropyl-)benzamide. However, the physicochemical properties and toxicological data of the substance including the key determinants for a rational prediction of the toxicokinetic behavior in organisms do support in performing the assessment.
The physicochemical properties (i.e. low molecular weight, high water solubility and favourable log Powvalue) ofN,N-bis(2-hydroxypropyl-) benzamide enable the substance to readily pass biomembranes when exposed to organisms. The absorption rate for oral, dermal and inhalation routes are considered efficient (100% as worst case assumed for all three routes of exposure).
After absorption,N,N-bis(2-hydroxypropyl-)benzamide is expected to distribute widely in the body and the target organ would be possibly the liver. The substance is expected to be either excreted in form of parent molecules or broken down tobenzoic acid and aliphatic amine, further metabolized to hippuric acid andN-acetylation conjugate, which do become eliminated from the body. Accumulation in the body is therefore not expected forN,N-bis(2-hydroxypropyl-)benzamide.
Reference
Description of key information
Absorption rates were determined to be 100% for all routes of exposure, assuming a worst-case scenario.
No bioaccumulation of the substance in the body is expected.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
